RBC Capital analyst Conor McNamara maintained a Buy rating on Repligen (RGEN – Research Report) on April 1 and set a price target of $219.00.

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going ...

Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

This quarter, Repligen’s $167.5 million of revenue was flat year on year and in line with Wall Street’s estimates. Looking ahead, sell-side analysts expect revenue to grow 9% over the next 12 ...

Repligen Co. has a twelve month low of $113.50 and a twelve month high of $184.98. The company has a market cap of $7.49 billion, a P/E ratio of -261.59, a price-to-earnings-growth ratio of 4.54 ...

Base revenue (Non-GAAP) excludes COVID-related revenue and acquisition-related revenue contribution in current period for which there was no prior year comparable. For the three- and twelve-month ...

Learn more about whether Medpace Holdings, Inc. or Repligen Corporation is a better investment based on AAII's A+ Investor ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In the latest quarter, 6 analysts provided ratings for Repligen (NASDAQ:RGEN), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ ...

Repligen Corporation (NASDAQ:RGEN), a leading pure-play bioprocess supplier with a market capitalization of $8.17 billion, has been navigating a complex market environment characterized by ...